Oral Bioavailability of Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide in a 4-Drug Fixed-Dose Combination Compared With the Separate Formulations in Healthy Chinese Male Volunteers

Clinical Therapeutics

Volumn 35, Issue 2, 2013, Pages 161-168

  Xu, Jian ^a   Jin, Haixia ^a   Zhu, Hui ^a   Zheng, Meiqin ^a   Wang, Bin ^a   Liu, Chengcheng ^a   Chen, Mingting ^b   Zhou, Lin ^b   Zhao, Weijie ^a   Fu, Lei ^a   Lu, Yu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b National Center for Tuberculosis Control and Prevention   (China)

Author keywords

Bioavailability; Bioequivalence; Combination; Fixeddose; Pharmacokinetics; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FILM COATING; FIXED DOSE COMBINATION; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG COMBINATIONS; ETHAMBUTOL; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 84873607297     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.01.003     Document Type: Article

References (17)

1. Global Tuberculosis Report 2012 2012, World Health Organization, WHO, Geneva, Switzerland, Accessed November 26, 2012. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf.
2. Nationwide Anti-tuberculosis Drug Resistant Baseline Surveillance in China (2007-2008) [in Chinese] 2010, Ministry of Health of the People's Republic of China, People's Public Health Press, Beijing, China.
3. Zhao Y., Xu S., Wang L., et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012, 366:2161-2170.
4. Lienhardt C., Cook S.V., Burgos M., et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 2011, 305:1415-1423. Study C Trial Group.
5. Bartacek A., Schütt D., Panosch B., et al. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009, 13:760-766. Rimstar 4-FDC Study Group.
6. Treatment of Tuberculosis: Guidelines 2010, World Health Organization, WHO, Geneva, Switzerland, Accessed November 26, 2012. http://www.whqlibdoc.who.int/publications/2010/9789241541547833_eng.pdf, 4th ed.
7. China the General Office of the State Council, National Plan for Prevention and Control of Tuberculosis (2011-2015) [in Chinese] Accessed November 26, 2012. http://www.gov.cn/gongbao/content/2011/content_2020914.htm.
8. Laserson K.F., Kenyon A.S., Kenyon T.A., et al. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuberc Lung Dis 2001, 5:448-454.
9. Immanuel C., Gurumurthy P., Ramachandran G., et al. Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. Indian J Med Res 2003, 118:109-114.
10. Milán-Segovia R.C., Domínguez-Ramírez A.M., Jung-Cook H., et al. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. Int J Tuberc Lung Dis 2010, 14:1454-1460.
11. Agrawal S., Kaur K.J., Singh I., et al. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations. Int J Tuberc Lung Dis 2005, 9:1273-1280.
12. Agrawal S., Kaur K.J., Singh I., et al. Determination of rifampicin bioequivalence in a three-drug FDC by WHO and Indian protocols: effect of sampling schedule and size. Int J Tuberc Lung Dis 2005, 9:75-80.
13. Zhu Hui, Li Peng, Lu Yu LC-MS/MS determination of isoniazid, ethambutol and pyrazinamide in human plasma [in Chinese]. Chin J Pharm Anal 2012, 32:11-15.
14. Guidance for Industry. Bioanalytical method validation (updated 2001) Accessed November 26, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
15. Annex 8: proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. WHO Technical Report Series No 937 2006, World Health Organization, WHO, Geneva, Switzerland, Accessed November 26, 2010. http://apps.who.int/prequal/info_general/documents/TRS937/WHO_TRS_937__annex8_eng.pdf.
16. Agrawal S., Singh I., Kaur K.J., et al. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2004, 276:41-49.
17. Panchagnula R., Sancheti P., Rungta S., et al. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol. Pharmacol Res 2003, 48:383-387.